Abstract
We sought to evaluate the safety and efficacy of available biologics that inhibit T-cell migration by blocking α4β7 integrins in inflammatory bowel diseases. The aim of this study is to evaluate whether Crohn disease (CD) patients receiving either vedolizumab or natalizumab have any different effect in CD Activity Index (CDAI). Using Medline, Excerpta Medica dataBASE, Cochrane Central Register of Controlled Trials (CENTRAL), and Google Scholar until October 31, 2013, we identified 10 studies examining the safety and efficacy of specific integrin inhibitors—vedolizumab, which targets an epitope comprising the α4β7 heterodimer; natalizumab, which recognizes the α4 integrin subunit; etrolizumab, which is specific for the β7 subunit—in the treatment of CD and ulcerative colitis (UC). CD patients receiving either vedolizumab or natalizumab demonstrated a modest increase in remission rate, when compared with that of the placebo group. Further, although both treatments reduced the CDAI slightly, the observed clinical response was less robust than that of the remission rate. UC patients treated with vedolizumab and natalizumab were found to show more prominent increases in both remission and clinical response, compared with placebo, th...Continue Reading
References
Mar 23, 1999·Journal of Clinical Epidemiology·A P VerhagenP G Knipschild
Aug 7, 2001·Gastroenterology·F H GordonR E Pounder
Jan 3, 2003·The New England Journal of Medicine·Subrata GhoshUNKNOWN Natalizumab Pan-European Study Group
Jan 3, 2003·The New England Journal of Medicine·Ulrich H von Andrian, Britta Engelhardt
Jun 17, 2005·The New England Journal of Medicine·Brian G FeaganMargaret K Vandervoort
Jul 29, 2005·Immunological Reviews·Marko Salmi, Sirpa Jalkanen
Jul 30, 2005·European Journal of Immunology·Britta Engelhardt, Michael J Briskin
Nov 4, 2005·The New England Journal of Medicine·William J SandbornUNKNOWN Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group
May 9, 2007·Gastroenterology·Stephan R TarganUNKNOWN International Efficacy of Natalizumab in Crohn's Disease Response and Remission (ENCORE) Trial Group
May 15, 2007·Lancet·Daniel C Baumgart, William J Sandborn
Oct 3, 2008·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Brian G FeaganAsit Parikh
Jun 11, 2009·The Journal of Pharmacology and Experimental Therapeutics·Dulce SolerEric R Fedyk
Jul 23, 2009·Annals of Internal Medicine·Alessandro LiberatiDavid Moher
Oct 18, 2011·Gastroenterology·Natalie A MolodeckyGilaad G Kaplan
Nov 4, 2011·The New England Journal of Medicine·Silvio Danese, Claudio Fiocchi
Dec 8, 2011·Inflammatory Bowel Diseases·Asit ParikhBrian G Feagan
May 18, 2012·The New England Journal of Medicine·Gary BloomgrenCarmen Bozic
Jun 22, 2012·Gut·Paul J RutgeertsSharon O'Byrne
Feb 12, 2013·Expert Opinion on Biological Therapy·Mahmoud H Mosli, Brian G Feagan
Apr 30, 2013·Current Drug Targets·Giorgos BamiasJesús Rivera-Nieves
Aug 24, 2013·The New England Journal of Medicine·Brian G FeaganUNKNOWN GEMINI 1 Study Group
Aug 24, 2013·The New England Journal of Medicine·William J SandbornUNKNOWN GEMINI 2 Study Group
Nov 20, 2013·Digestive Diseases·Klaus Fellermann
Jan 22, 2014·Alimentary Pharmacology & Therapeutics·C J M WilliamsA C Ford
Jan 30, 2014·PloS One·Ruxi LvXuebao Zheng
Feb 11, 2014·Alimentary Pharmacology & Therapeutics·R W StidhamA K Waljee
Citations
Jun 4, 2015·Current Opinion in Gastroenterology·Paula Sousa, Matthieu Allez
Mar 16, 2017·Inflammatory Bowel Diseases·Sebastian Zundler, Markus F Neurath
Aug 2, 2018·The Cochrane Database of Systematic Reviews·Seana Ml NelsonJohn K MacDonald
Nov 18, 2018·Expert Opinion on Therapeutic Patents·Hao LiJi-Fu Wei
May 23, 2018·Inflammatory Bowel Diseases·Amy HemperlyNiels Vande Casteele
Feb 1, 2017·Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·Z A GoncharovaV A Megeryan
Feb 6, 2020·Immunological Investigations·Hao-Yue ZhouBao-Zhu Li
Feb 22, 2017·Inflammatory Bowel Diseases·Sebastian ZundlerMarkus F Neurath
Oct 1, 2016·Pharmacological Reports : PR·Paweł MoćkoAndrzej Pilc
Apr 5, 2017·World Journal of Gastroenterology : WJG·Michael K ZhengGary C Chen
Apr 4, 2018·The American Journal of Gastroenterology·Gary R LichtensteinBruce E Sands
Feb 19, 2019·Frontiers in Pharmacology·Charlotte LichnogSebastian Zundler
Jul 14, 2019·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Pavine L C LefevreNiels Vande Casteele
Jun 18, 2016·Pharmacotherapy·Paweł MoćkoAndrzej Pilc
May 4, 2021·Frontiers in Pharmacology·Badr Al-BawardyDeborah D Proctor